NextCure Inc Asset Resilience Ratio
NextCure Inc asset resilience ratio. NextCure Inc (NXTC) has an Asset Resilience Ratio of 21.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of NextCure Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NextCure Inc (2017–2025)
Asset resilience ratio of NextCure Inc from 2017 to 2025. This chart shows how NextCure Inc's Asset Resilience Ratio has changed over time. Read NXTC total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NextCure Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NXTC asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.83 Million | 21.34% |
| Total Liquid Assets | $4.83 Million | 21.34% |
Asset Resilience Insights
- Good Liquidity Position: NextCure Inc maintains a healthy 21.34% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
NextCure Inc Industry Peers by Asset Resilience Ratio
Compare NextCure Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
NextCure Inc Asset Resilience Ratio by Year (2017–2025)
NextCure Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for NextCure Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.56% | $15.84 Million | $50.18 Million | -19.02pp |
| 2024-12-31 | 50.57% | $40.89 Million | $80.86 Million | -23.79pp |
| 2023-12-31 | 74.37% | $95.22 Million | $128.04 Million | +1.99pp |
| 2022-12-31 | 72.37% | $133.28 Million | $184.16 Million | -13.13pp |
| 2021-12-31 | 85.51% | $207.25 Million | $242.39 Million | +3.76pp |
| 2020-12-31 | 81.75% | $250.68 Million | $306.64 Million | -2.63pp |
| 2019-12-31 | 84.37% | $300.51 Million | $356.17 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $147.63 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $19.47 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more